Stocks · News reference
Evotec Affirms FY2026 Sales Guidance of $667.470M-$714.310M vs $673.750M Est
Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $667.470 million-$714.310 million to $667.470 million-$714.310 million vs $673.750 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 8:49 AM
- Checked
- Aug 13, 2026, 8:49 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same
Read original at benzingaOdyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's
Read original at benzinga